Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial

Morice, Marie-Claude; W. Serruys, Patrick; Pieter Kappetein, A.; Feldman, Ted; Ståhle, Elisabeth; Colombo, Antonio; J. Mack, Michael; R. Holmes, David; Torracca, Lucia; van Es, Gerrit-Anne; Leadley, Katrin; D. Dawkins, Keith; W. Mohr, Friedrich

doi:10.1161/circulationaha.109.899211

Public

Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial

Published in Circulation • Jun 8, 2010

Authors:

Marie-Claude Morice

Patrick W. Serruys

A. Pieter Kappetein

Abstract

BACKGROUND: The prospective, multinational, randomized Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was designed to assess the optimal revascularization strategy between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (...

Subject

Medicine

Conventional PCI

Percutaneous coronary intervention

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!